Campochiaro C, Della-Torre E, Lanzillotta M, et al. - Fourteen people with IgG4-RD were treated with Rituximab (RTX) as induction of remission therapy at the San Raffaele Scientific Institute in Milan, Italy, experts intend to assess the effectiveness and safety of RTX for maintenance of IgG4-RD remission. The cohort was then divided into two research groups such as people re-treated only in case of disease relapse, and people regularly re-treated with RTX every 6 months for maintenance therapy. Average follow-up time and baseline clinical-serological characteristics were alike between both research groups. It was found that the administration of RTX every 6 months as maintenance of remission therapy prevents IgG4-RD flares.